$2.59T
Total marketcap
$165.51B
Total volume
BTC 50.15%     ETH 15.76%
Dominance

Apellis Pharmaceuticals APLS Stock

56.26 USD {{ price }} -0.845970% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
6.78B USD
LOW - HIGH [24H]
55.97 - 57.48 USD
VOLUME [24H]
908.98K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-4.45 USD

Apellis Pharmaceuticals Price Chart

Apellis Pharmaceuticals APLS Financial and Trading Overview

Apellis Pharmaceuticals stock price 56.26 USD
Previous Close 92.12 USD
Open 91.55 USD
Bid 0 USD x 800
Ask 0 USD x 1000
Day's Range 88.81 - 91.91 USD
52 Week Range 42.15 - 94.75 USD
Volume 1.23M USD
Avg. Volume 1.56M USD
Market Cap 10.43B USD
Beta (5Y Monthly) 1.245422
PE Ratio (TTM) N/A
EPS (TTM) -4.45 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 105.14 USD

APLS Valuation Measures

Enterprise Value 9.77B USD
Trailing P/E N/A
Forward P/E -30.580204
PEG Ratio (5 yr expected) -0.52
Price/Sales (ttm) 98.544174
Price/Book (mrq) 25.260784
Enterprise Value/Revenue 92.29
Enterprise Value/EBITDA -15.291

Trading Information

Apellis Pharmaceuticals Stock Price History

Beta (5Y Monthly) 1.245422
52-Week Change 102.99%
S&P500 52-Week Change 20.43%
52 Week High 94.75 USD
52 Week Low 42.15 USD
50-Day Moving Average 86.29 USD
200-Day Moving Average 64.23 USD

APLS Share Statistics

Avg. Volume (3 month) 1.56M USD
Avg. Daily Volume (10-Days) 1.17M USD
Shares Outstanding 116.46M
Float 88.6M
Short Ratio 7.41
% Held by Insiders 13.98%
% Held by Institutions 88.61%
Shares Short 11.36M
Short % of Float 11.39%
Short % of Shares Outstanding 9.75%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -605.077%
Gross Margin 70.45%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -37.69%
Return on Equity (ttm) -158.061%

Income Statement

Revenue (ttm) 105.89M USD
Revenue Per Share (ttm) 0.96 USD
Quarterly Revenue Growth (yoy) 211.79%
Gross Profit (ttm) 69.79M USD
EBITDA -639102016 USD
Net Income Avi to Common (ttm) -691014976 USD
Diluted EPS (ttm) -6.04
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 774.12M USD
Total Cash Per Share (mrq) 6.65 USD
Total Debt (mrq) 111.87M USD
Total Debt/Equity (mrq) 27.15 USD
Current Ratio (mrq) 6.883
Book Value Per Share (mrq) 3.547

Cash Flow Statement

Operating Cash Flow (ttm) -579804992 USD
Levered Free Cash Flow (ttm) -349684864 USD

Profile of Apellis Pharmaceuticals

Country United States
State MA
City Waltham
Address 100 Fifth Avenue
ZIP 02451
Phone 617 977 5700
Website https://www.apellis.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 767

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Q&A For Apellis Pharmaceuticals Stock

What is a current APLS stock price?

Apellis Pharmaceuticals APLS stock price today per share is 56.26 USD.

How to purchase Apellis Pharmaceuticals stock?

You can buy APLS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Apellis Pharmaceuticals?

The stock symbol or ticker of Apellis Pharmaceuticals is APLS.

Which industry does the Apellis Pharmaceuticals company belong to?

The Apellis Pharmaceuticals industry is Biotechnology.

How many shares does Apellis Pharmaceuticals have in circulation?

The max supply of Apellis Pharmaceuticals shares is 120.58M.

What is Apellis Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Apellis Pharmaceuticals PE Ratio is now.

What was Apellis Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Apellis Pharmaceuticals EPS is -4.45 USD over the trailing 12 months.

Which sector does the Apellis Pharmaceuticals company belong to?

The Apellis Pharmaceuticals sector is Healthcare.

Apellis Pharmaceuticals APLS included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD